Inositol nicotinate
产品说明书
 |
同义名 : | Inositol niacinate; Hexanicit; Palohex; Dilcit; Dilexpal; Mesonex; NSC 49506; Myo-Inositol hexanicotinate; Inositol hexanicotinate |
| CAS号 : | 6556-11-2 | |
| 货号 : | A991083 | |
| 分子式 : | C42H30N6O12 | |
| 纯度 : | 97% | |
| 分子量 : | 810.72 | |
| MDL号 : | MFCD00006387 | |
| 存储条件： |
Pure form Inert atmosphere, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Inositol nicotinate is a form of niacin, also known as vitamin B3, which is an essential nutrient for the human body. Inositol nicotinate has the effect of lowering cholesterol and dilating peripheral blood vessels. It is used in hypercholesterolemia and atherosclerosis. The thermographic index for both the dorsum of the hand and the fingers was significantly lower in the patients with Raynaud's. Oral treatment with inositol nicotinate (Hexopal) was followed by an initial rise in the thermographic index in both areas. Long-term treatment with nicotinate acid derivatives may produce improvement in the peripheral circulation by a different mechanism than the transient effect detected by short-term studies[1]. Recording the time required to induce Raynaud's phenomenon as well as assessments of total and nutrient digital blood flow showed significant beneficial therapeutic effects upon the skin's microcirculation by inositol nicotinate. Unlike some other drugs in this field inositol nicotinate was found to be effective orally and to be devoid of unwanted side-effects[2]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01139398 | Delivery of Health Care | Not Applicable | Completed | - | France ... 展开 >> Biofortis Nantes, France, 44200 收起 << |
| NCT03630991 | Acute Myeloid Leukemia ... 展开 >> Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasm Secondary Acute Myeloid Leukemia 收起 << | Phase 2 | Recruiting | December 31, 2020 | United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact mohanian@mdanderson.org 收起 << |
| NCT01488656 | Inflammation | Not Applicable | Completed | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.23mL 0.25mL 0.12mL |
6.17mL 1.23mL 0.62mL |
12.33mL 2.47mL 1.23mL |
| 参考文献 |
|---|